Other languages Senseonics Holdings, Inc.

Equities

SENS

US81727U1051

Market Closed - Nyse Other stock markets 16:00:00 2024-06-21 EDT			5-day change	1st Jan Change
0.38 ^USD	-2.56%		-2.91%	-33.35%

06-23	Transcript : Senseonics Holdings, Inc. - Shareholder/Analyst Call
06-21	Senseonics Expects 2024 Net Revenue $22 Million to $24 Million	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Senseonics Expects 2024 Net Revenue $22 Million to $24 Million	06-21
Senseonics Holdings, Inc. Reaffirms Revenue Guidance for the First Half and Provides Revenue Guidance for the Full Year of 2024	06-21
Senseonics Holdings, Inc. Provides Earnings Guidance for the First Half 2024	05-13
Senseonics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13
Senseonics Holdings, Inc. and Mercy Collaborate to Improve Diabetes Population Health Management	05-13
Senseonics Partners with Rimidi to Develop Innovative Diabetes Solution	05-09
Senseonics Holdings, Inc. Announces Eversense CGM System Receives iCGM Designation by the U.S. Food and Drug Administration	04-30
Senseonics Holdings, Inc. Announces Board Changes	03-25
Senseonics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29
Senseonics Holdings, Inc. Provides Revenue Guidance for the First Half of 2024	02-29
Senseonics Q4 Revenue Guidance Tops Consensus	01-02
Senseonics Holdings, Inc. Provides Earnings Guidance for the Year 2023	11-09
Senseonics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Senseonics Holdings, Inc. Announces the Last Patient Completion of the 365-Day ENHANCE Pivotal Clinical Study	23-09-26
Insider Buy: Senseonics Holdings	23-08-31
Senseonics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Senseonics Holdings, Inc. Reiterates Revenue Guidance for the Full Year 2023	23-08-10
Sensonics Holdings, Inc. Announces New Clinical Data Demonstrating the Safety and Accuracy of Eversense Through 365 Days Presented at the American Diabetes Association 83rd Scientific Sessions	23-06-26
Senseonics Says UnitedHealthcare to Cover Eversense E3 Continuous Glucose Monitoring System; Shares Rise	23-06-02
Senseonics Holdings, Inc. Elects Koichiro Sato as Directors	23-05-23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Senseonics Holdings, Inc.

Equities

SENS

US81727U1051

Other languages

Filters